Rogocekib for the treatment of Refractory or Relapsed Acute Myeloid Leukemia (AML) has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA)

rogocekib (CTX-712) - Chordia Therap

Jan 10, 2025